(:CLVS)

Dec 12, 2022 09:41 am ET
Thinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, BAC, RIVN, RENT, and VIPS.
Dec 12, 2022 12:18 am ET
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process.
Nov 15, 2022 11:15 am ET
Thinking about buying stock in Pineapple Energy, Nio, SoFi Technologies, Clovis Oncology, or Rivian Automotive?
NEW YORK, Nov. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PEGY, NIO, SOFI, CLVS, and RIVN.
Oct 27, 2022 05:05 pm ET
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, “Novel Clinical Trial Updates” at the 29
Oct 17, 2022 03:45 am ET
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) i
Oct 03, 2022 08:30 am ET
Thinking about buying stock in Myovant Sciences, Clovis Oncology, FingerMotion, LogicBio Therapeutics, or Amplify Energy?
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYOV, CLVS, FNGR, LOGC, and AMPY.
Oct 03, 2022 07:00 am ET
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide. Benefit was observed in both primary efficacy analyses of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRP
Sep 21, 2022 08:00 am ET
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopia’s lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting t
Sep 13, 2022 09:31 am ET
Thinking about buying stock in Core & Main, Catalyst Pharmaceuticals, Ironsource, Clovis Oncology, or Oncternal Therapeutics?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNM, CPRX, IS, CLVS, and ONCT.
Sep 13, 2022 08:00 am ET
Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) and a Type II variation with the European Medicines Agency (EMA) for approval of Rubraca® (rucaparib) as first-line maintenance treatment for women with advanced ovarian cancer regardless of biomarker status who have responded to first-line platinum-based chemotherapy.
Sep 12, 2022 09:31 am ET
Thinking about buying stock in Regulus Therapeutics, Nio, AMC Entertainment, Carvana, or Clovis Oncology?
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RGLS, NIO, AMC, CVNA, and CLVS.
Sep 11, 2022 10:30 am ET
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO). These data showed that Rubraca as first-line maintenance treatment improved progression-free survival (PFS) versus placebo across disease risk subgroups including surgical outcome, response to first-line chemotherapy, and additional analyses in other subgroups. The data were presented by Rebecca S. Kristeleit, MD, PhD, of Guy’s and St. Thomas’ NHS Foundation Trust in London and lead ENGOT/NCRI
Aug 08, 2022 08:00 am ET
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2022, and provided an update on the Company’s
Jul 20, 2022 06:06 pm ET
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in greater detail. (instead of Clovis’ senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis’ results and business outlook in greater detail.).
Jul 20, 2022 04:00 pm ET
Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.
Jul 13, 2022 10:55 am ET
Thinking about buying stock in Humanigen, Endo International, Kura Oncology, Delta Air Lines, or Clovis Oncology?
NEW YORK, July 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, ENDP, KURA, DAL, and CLVS.
Jun 22, 2022 09:31 am ET
Thinking about buying stock in Energy Focus, Ford Motor, Clovis Oncology, Li Auto, or Rigel Pharmaceuticals?
NEW YORK, June 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, F, CLVS, LI, and RIGL.
Jun 21, 2022 08:30 am ET
Thinking about buying stock in Clovis Oncology, Advent Technologies, DBV Technologies, Powerbridge Technologies, or Spirit Airlines?
NEW YORK, June 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, ADN, DBVT, PBTS, and SAVE.
Jun 15, 2022 08:30 am ET
Thinking about buying stock in Clovis Oncology, Revlon, Sundial Growers, Xpeng, or Bitnile?
NEW YORK, June 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, REV, SNDL, XPEV, and NILE.
Jun 14, 2022 02:00 pm ET
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activit
Jun 14, 2022 11:10 am ET
Thinking about buying stock in Clovis Oncology, Houston American Energy, Soleno Therapeutics, SeaChange International, or Norwegian Cruise Line?
NEW YORK, June 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, HUSA, SLNO, SEAC, and NCLH.
Jun 06, 2022 08:00 am ET
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardles
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the first presentation of data from the monotherapy arm of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO) as a late-breaking oral abstract (LBA5500) to be presented on Monday, June 6, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data demonstrate that Rubraca as first-line maintenance treatment significantly improved investigator-assessed progression-free survival (PFS) compared with placebo in women with advanced ovarian cancer irrespective of biomarker status. The results
May 06, 2022 10:55 am ET
Thinking about buying stock in Vinco Ventures, Digital Brands, Endo, Clovis Oncology, or Under Armour?
NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, DBGI, ENDP, CLVS, and UAA.
May 05, 2022 08:00 am ET
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference will be held at the Encore hotel in Las Vegas.
May 04, 2022 08:00 am ET
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Company’s
Apr 28, 2022 08:00 am ET
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data from the ATHENA-MONO Phase 3 clinical trial evaluating Rubraca monotherapy versus placebo and imaging of solid tumors using FAP-2286, will be presented in oral and poster sessions during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held June 3-7, 2022, in Chicago. Three additional retrospective analyses evaluating Rubraca and PARP inhibitors will be published online during the meeting.
Apr 20, 2022 08:00 am ET
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.
Apr 08, 2022 08:00 am ET
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that two abstracts featuring non-clinical data from studies evaluating FAP-2286 and Rubraca and a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE study will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans.
Apr 06, 2022 08:31 am ET
Thinking about buying stock in Citius Pharmaceuticals, BioXcel Therapeutics, Array Technologies, Gogo, or Clovis Oncology?
NEW YORK, April 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, BTAI, ARRY, GOGO, and CLVS.
Mar 31, 2022 06:00 am ET
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the monotherapy arm of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca as maintenance treatment successfully achieved the primary endpoint of significantly improved investigator-assessed progression-free survival (PFS) compared with placebo. Benefit was observed in both primary efficacy analyses of newly-diagnosed patients with advanced ovarian cancer following successful treatment with platinum-based chemotherapy: those who had homologous recombination deficiency (HRD-positive)
Mar 16, 2022 08:00 am ET
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). Under the agreement, Clovis and Evergreen intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies.
Mar 09, 2022 08:31 am ET
Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca?
NEW YORK, March 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, NCLH, MARA, CLVS, and BCEL.
Feb 25, 2022 08:00 am ET
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a presentation titled “Initial Experience with FAP-2286 Imaging” related to an ongoing investigator-initiated trial (IIT) evaluating the ability of imaging agent gallium-68 (68Ga)-FAP-2286 to detect metastatic cancer in patients with solid tumors. These data will be presented by Thomas A. Hope, M.D., Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the Uni
Feb 23, 2022 08:05 am ET
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s
Feb 10, 2022 04:05 pm ET
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.
Jan 10, 2022 08:00 am ET
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Dec 09, 2021 08:00 am ET
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today’s presentation by Andrew D. Simmons, Ph.D., Clovis’ Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals Summit being held virtually December 7-9, 2021. Dr. Simmons’ presentation, titled “Innovations in Peptide Targeted Radionuclide Therapies (PTRT) to Target Fibroblast Activation Protein (FAP) in Solid Tumors”, reviews the Company’s preclinical data and describes the Phase 1/2 study currently enrolling for its targeted radiotherapy candidate FAP-2286, the first PTRT and imaging agent targeting FAP to enter
Nov 03, 2021 08:00 am ET
Clovis Oncology Announces Third Quarter 2021 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s
Oct 20, 2021 08:00 am ET
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.
Oct 19, 2021 08:00 am ET
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotop
Oct 07, 2021 09:00 am ET
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7-10, 2021. The analysis, conducted with its partner 3B Pharmaceuticals GmbH, measured FAP expression in multiple tumor types using immunohistochemistry (IHC) as well as the correlation between FAP expression by IHC and in vitro binding of FAP-2286, Clovis’ peptide-targeted radionuclide
Sep 20, 2021 08:00 am ET
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due 2021. In addition, the Company provided an update on the progress of its renewed “at-the-market” (ATM) equity offering program announced in mid-August, pursuant to which it has sold during the third quarter of 2021 to date an aggregate of approximately 9.4 million shares of its common stock for gross proceeds of approximately $43.0 million and resulting in net proceeds to Clovis Oncology of approximate
Aug 24, 2021 02:00 am ET
Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic products (Swissmedic)i gave a positive recommendation for Rubraca as maintenance treatment for recurrent platinum sensitive ovarian cancer.2 Rubraca is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.2
Aug 16, 2021 04:21 pm ET
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) to renew its previously established ATM facility under which it may offer and sell, from time to time, additional shares of its common stock having an aggregate offering price of up to $125,000,000 through an “at-the-market” equity offering program (the “ATM Program”). The timing and amount of any sales will be determined by a variety of factors considered by Clovis Oncology.
Aug 04, 2021 08:00 am ET
Clovis Oncology Announces Second Quarter 2021 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2021, and provided an update on the Company’s
Jul 21, 2021 08:00 am ET
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.
Jul 16, 2021 11:15 am ET
Thinking about buying stock in Cinedigm, VEON, Alcoa, Clovis Oncology, or Skillz?
NEW YORK, July 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CIDM, VEON, AA, CLVS, and SKLZ.
Jul 14, 2021 09:31 am ET
Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?
NEW YORK, July 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AHT, CLVS, XELA, WIT, and ATOS.
Jul 13, 2021 09:31 am ET
Thinking about buying stock in Nokia, Clovis Oncology, Avinger, Ericsson, or New Oriental Education?
NEW YORK, July 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, CLVS, AVGR, ERIC, and EDU.
Jul 12, 2021 04:05 pm ET
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today.
Jul 12, 2021 11:30 am ET
Thinking about buying stock in Toughbuilt Industries, MER Telemanagement Solutions, United Airlines, AST SpaceMobile, or Clovis Oncology?
NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, MTSL, UAL, ASTS, and CLVS.
Jun 28, 2021 07:00 am ET
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals (Clovis’ licensing partner and discoverer of FAP-2286), published a retrospective report of their independent experience with FAP-2286 in named-patient use in
Jun 23, 2021 07:00 am ET
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP), is now open at the O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB).
Jun 10, 2021 04:30 pm ET
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
Clovis Oncology, Inc. (NASDAQ:CLVS) (the “Company”) today announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Company adjourned the Annual Meeting solely with respect to Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2021 (as supplemented, “Proxy Statement”). Proposal 2 is a proposal to amend the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock the Company is authorized to issue f
Jun 09, 2021 09:31 am ET
Thinking about buying stock in The GEO Group, Orbital Energy, Clover Health, Clovis Oncology, or Energous Corp?
NEW YORK, June 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEO, OEG, CLOV, CLVS, and WATT.
May 19, 2021 06:27 pm ET
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real world data of PARP inhibitor usage, will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021.
May 17, 2021 04:15 pm ET
Clovis Oncology Announces At-The-Market Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $75,000,000 million through an “at-the-market” equity offering program (the “ATM Program”). The timing and amount of any sales will be determined by a variety of factors considered by Clovis Oncology.
May 05, 2021 08:00 am ET
Clovis Oncology Announces First Quarter 2021 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2021, and provided an update on the Company’s
Apr 28, 2021 04:05 pm ET
Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021, at 5:00 p.m. Eastern time.
Apr 21, 2021 04:00 pm ET
Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.
Apr 10, 2021 08:30 am ET
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021.
Mar 19, 2021 08:00 am ET
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer (SGO). The data demonstrate that Rubraca significantly improves PFS compared to standard-of-care chemotherapy, including platinum-based chemotherapy, among patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation who have received two or more prior lines of chemotherapy.
Feb 25, 2021 08:31 am ET
Thinking about buying stock in Workhorse Group, Sundial Growers, Nokia, Clovis Oncology, or Compugen?
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, SNDL, NOK, CLVS, and CGEN.
Feb 23, 2021 08:00 am ET
Clovis Oncology Announces 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company’s
Feb 17, 2021 08:00 am ET
Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.
Feb 11, 2021 08:00 am ET
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca data being presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium 2021. These include data from the Phase 1b RAMP study evaluating Rubraca in combination with Xtandi, exploratory analyses from the pivotal TRITON2 study, and an analysis evaluating the rates of adverse events for different metastatic castration-resistant prostate cancer (mCRPC) treatments in a population of insured patients in the United States.
Feb 04, 2021 08:00 am ET
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC) and one abstract describing adverse events associated with mCRPC treatment based on real world evidence have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021.
Jan 27, 2021 08:31 am ET
Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR.
Jan 11, 2021 08:00 am ET
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Dec 29, 2020 08:00 am ET
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286, the lead compound in its peptide-targeted radionuclide therapy (PTRT) development program. Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical study of lutetium-177 labeled FAP-2286 (177Lu-FAP-2286) to determine the dose and tolerability of the FAP-targeting therapeutic agent (Phase 1), with expansion cohorts planned in multiple tumor types (Phas
Dec 21, 2020 08:31 am ET
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR.
Dec 21, 2020 08:00 am ET
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ova
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy in relapsed ovarian cancer patients with a tumor mutation of BRCA who have received two or more prior lines of chemotherapy.
Nov 24, 2020 06:06 pm ET
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that pursuant to the terms of that previously announced Exchange and Purchase Agreement, dated as of November 4, 2020, by and between Clovis Oncology and an existing holder of its securities named therein (the “Holder”) relating to the offering of the Company’s new series of 4.50% Convertible Senior Notes due 2024 (the “New 2024 Notes”), such Holder has elected to exercise its option to purchase an additional $7.5 million aggregate principal amount of the New 2024 Notes on the same terms. The settlement of the option is expected to occur on
Nov 20, 2020 08:00 am ET
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part of the Piper Sandler 32nd Annual Healthcare Conference. The virtual conference, which takes place November 30 to December 3, 2020, incorporates a library of pre-recorded fireside chat presentations with presenting companies available on Monday, November 23, 2020 at 10:00 a.m. Eastern time.
Nov 05, 2020 08:05 am ET
Clovis Oncology Announces Third Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company’s
Oct 20, 2020 04:05 pm ET
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
Sep 17, 2020 03:05 am ET
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from the Phase 1b part of the LIO-1 study of lucitanib in combination with Opdivo, new analyses of data from the pivotal Rubraca ARIEL3 and TRITON2 studies, initial data from the Phase 1b part of the SEASTAR study arm of Rubraca with Trodelvy™ (sacituzumab govitecan-hziy), and the first presentation of preclinical data for FAP-2286 Clovis’ novel peptide-targeted radionuclide therapy.
Sep 10, 2020 08:05 am ET
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca® (rucaparib) as maintenance treatment in recurrent ovarian cancer has been accepted for presentation in an oral plenary session at the International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting taking place September 10–13. The findings of the analysis demonstrate that rucaparib maintenance treatment can lead to a clinically meaningful delay in starting subsequent therapy and lasting clinical benefits in
Sep 09, 2020 08:05 am ET
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca® (rucaparib) clinical development programs, as well as preclinical data for FAP-2286, will be presented at the ESMO (European Society for Medical Oncology) Virtual Congress 2020, September 19 – September 21, 2020.
Sep 08, 2020 04:19 pm ET
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 2:00 p.m. Eastern time.
Aug 26, 2020 07:23 pm ET
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca ® (rucaparib) tablets, recently approved for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based
Aug 17, 2020 08:05 am ET
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations were published online in the Journal of Clinical Oncology. These results supported the May 2020 U.S. Food and Drug Administration (FDA) accelerated approval of Rubraca for the treatment of mCRPC patients who have a deleterious BRCA mutation (germline and/or somatic) and who have previously received androgen receptor-directed therapy and taxan
Aug 06, 2020 04:05 pm ET
Clovis Oncology Announces Second Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s
Aug 05, 2020 08:05 am ET
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational angiogenesis inhibitor, including vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), and Opdivo® (nivolumab), Bristol Myers Squibb’s PD-1 inhibitor, for the treatment of gynecologic cancers. The LIO-1 trial is sponsored by Clovis as part of its broad clinical collaboration with Bristol Myers Squibb.
Jul 23, 2020 08:00 am ET
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Jun 22, 2020 09:01 am ET
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, with lucitanib, Clovis' investigational angiogenesis inhibitor. The data will be presented during a poster session at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place June 22-24, 2020.
Jun 17, 2020 08:00 am ET
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and publication at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22 - 24, 2020.
Jun 10, 2020 04:05 pm ET
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO® (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer. ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design.
May 28, 2020 08:00 am ET
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new recommendations for Rubraca® (rucaparib) tablets.i In addition to its ovarian cancer recommendations, Rubraca is now recommended in the NCCN Guidelines® for the treatment of BRCA-mutant patients with mCRPC under second-line treatment and subsequent therapy as a Category 2A recommendation inclusive of the following:
May 21, 2020 04:10 pm ET
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have been accepted for presentation or publication at the American Society of Clinical Oncology 2020 Virtual Scientific Program taking place May 29 – 31.
May 18, 2020 08:05 pm ET
Clovis Oncology Announces Pricing of Public Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriters a 30-day option to purchase up to an additional 1,663,500 shares of its common stock on the same terms and conditions.
May 18, 2020 04:02 pm ET
Clovis Oncology Announces Proposed Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.
May 15, 2020 02:30 pm ET
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recepto
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The FDA approved this indication under accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the multi-center, single arm TRITON2 clinica
May 05, 2020 04:05 pm ET
Clovis Oncology Announces First Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s
Apr 29, 2020 04:05 pm ET
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May 12, 2020 at 10:20 a.m. Eastern time.
Apr 21, 2020 04:05 pm ET
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Apr 14, 2020 05:08 pm ET
Mar 03, 2020 08:30 am ET
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 11:15 a.m. Eastern time. The conference will be held at the Loews Miami Beach Hotel in Miami.
Mar 02, 2020 04:00 am ET
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and Health Products approval of rucaparib for reimbursement. Rucaparib is now available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA sta
Feb 24, 2020 04:05 pm ET
Clovis Oncology Announces 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’
Feb 13, 2020 08:30 am ET
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Feb 11, 2020 04:05 pm ET
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 10:30 a.m. Eastern Standard Time. The conference will be held at the Lotte New York Palace in New York City.
Feb 03, 2020 04:00 am ET
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.2 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.2
Jan 15, 2020 08:00 am ET
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of May 15, 2020. Clovis submitted the sNDA submission for rucaparib as a monotherapy treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer in November 2019.
Jan 07, 2020 07:26 am ET
Clovis Oncology Announces Debt Refinancing Transaction
On a net basis, the Company will not receive any proceeds from the Transactions and will pay customary fees and expenses in connection therewith. Therefore, the Transactions will not have a material impact on the Company’s cash position. Following the Note Repurchase, an aggregate of $139,583,000 principal amount of the Company’s 2024 Notes will be outstanding.
Jan 07, 2020 07:25 am ET
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2019. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Dec 16, 2019 08:30 am ET
Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International Centers for Precision Oncology (ICPO) Foundation Symposium in Bad Berka, Germany. At Prof. Dr. Baum’s clinic, FAP-2286 was linked to Gallium-68 as a tumor-imaging compound using PET/CT and to Lutetium-177 as a therapeutic agent.
Nov 13, 2019 04:00 am ET
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3
Nov 07, 2019 08:00 am ET
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’
Oct 22, 2019 08:30 am ET
Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
Oct 11, 2019 09:19 am ET
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.
Sep 29, 2019 02:30 am ET
Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the E
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the potential of Rubraca® (rucaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA1/2 mutation. The data show a 43.9% confirmed objective response rate (ORR) by investigator assessment in 57 RECIST*/PCWG3** response-evaluable patients with a BRCA1/2 mutation. When assessed by independent radiological review, the respo
Sep 23, 2019 04:00 am ET
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Clovis Oncology, Inc. (NASDAQ: CLVS) has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas.1 Cl
Sep 12, 2019 04:00 am ET
Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that three posters highlighting studies from the Rubraca® (rucaparib) clinical development program will be presented at the ESMO (European Society for Medical Oncology) Congress 2019, September 27 – October 1, 2019, in Barcelona, Spain.
Aug 28, 2019 08:05 am ET
Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM Eastern Time. The conference will be held at the Westin Copley Place in Boston, MA.
Aug 22, 2019 05:42 pm ET
Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 4.50% Convertible Senior Notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to exercise their option to purchase an additional $13.0 million aggregate principal amount of the notes. The settlement of the option is expected to occur on August 23, 2019, subject to customary closing conditions. Following the closing, there will be a total of $263.0 m
Aug 08, 2019 06:26 pm ET
Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes
The notes will bear interest at a rate of 4.50% per annum, payable semi-annually in arrears on February 1st and August 1st of each year. The notes will mature on August 1, 2024 unless earlier converted or repurchased. The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date at an initial conversion rate of 137.2213 shares of Clovis Oncology’s common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $7.
Aug 07, 2019 04:10 pm ET
Clovis Oncology to Offer $225 Million of Convertible Senior Notes
The interest rate, conversion rate and other terms will be determined at the time of pricing of the offering of the notes. The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Clovis Oncology will not have the right to redeem the notes prior to their maturity. Holders of the notes may require Clovis Oncology to repurchase for cash all or part of their notes upon certain fundamental changes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased,
Aug 01, 2019 08:00 am ET
Clovis Oncology Announces Second Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2019, and provided an update on Clovis’
Jul 18, 2019 08:00 am ET
Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
Jun 06, 2019 04:05 pm ET
Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Ginger L. Graham as Board Chair to Clovis’ Board of Directors, following the retirement of former Board Chair Dr. M. James Barrett.
Jun 01, 2019 07:30 am ET
Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced multiple datasets being presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 – June 4, 2019. These include presentations of exploratory endpoint evaluations and updated safety data from the pivotal Phase 3 ARIEL3 trial evaluating Rubraca® (rucaparib) for the maintenance treatment of advanced ovarian cancer, as well as genomic characteristics of BRCA1/2 mutations among metastatic castration-resistant prostate cancer (mCRPC) patients in
May 20, 2019 04:05 pm ET
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced data demonstrating that patients with recurrent ovarian cancer who received Rubraca in the Phase 3 ARIEL3 study had longer periods of quality-adjusted time without clinically relevant symptoms as compared to patients who received placebo, and that Rubraca maintenance treatment continued to provide significant benefit in progression-free survival when weighted with patients’ perceptions of their wellbeing. The presentation today at the International Society for Pharmacoeconomics and Outcomes (I
May 16, 2019 08:00 am ET
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.
May 07, 2019 08:00 am ET
Clovis Oncology Announces First Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company’s
May 06, 2019 08:00 am ET
Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time. The conference will be held at the Encore Hotel in Las Vegas, Nevada.
May 02, 2019 08:00 am ET
Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. ATHENA is Clovis Oncology’s largest clinical trial, with a planned target enrollment of 1000 patients across more than 270 sites in at least 25 countries.
Apr 24, 2019 04:05 pm ET
Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
Apr 10, 2019 07:15 am ET
New Research: Key Drivers of Growth for Weatherford International, J. C. Penney, SBA Communications, Clovis Oncology, Gladstone Land, and BCE — Factors of Influence, Major Initiatives and Sustained Pr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Weatherford International PLC (NYSE:WFT), J. C. Penney Company, Inc....
Apr 02, 2019 08:30 am ET
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced multiple presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. These include today’s presentation of interim results from an investigator-initiated Phase 2 trial of Rubraca® (rucaparib) in platinum-sensitive patients with advanced pancreatic cancer. Early data from the study are encouraging and suggest that first-line maintenance therapy with Rubraca following induction with platinum-based chemotherapy p
Mar 19, 2019 08:00 am ET
Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place March 29 – April 3 in Atlanta.
Mar 16, 2019 12:45 pm ET
Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca will be presented during oral plenary and poster sessions at the Society of Gynecologic Oncology 2019 Congress (SGO), March 16 -19, 2019 in Honolulu, Hawaii. Data to be presented will highlight ARIEL3 results in different patient demographics, including age and deleterious germline mutation status.
Mar 06, 2019 04:19 pm ET
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 11:15 a.m. Eastern time. The conference will be held at the Loews Miami Beach Hotel in Miami.
Mar 06, 2019 07:00 am ET
New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group — Consolidated Revenues, Company Growth, and Expectations for
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS), Welltower Inc. (NYSE:WELL), The...
Mar 04, 2019 03:00 am ET
Clovis Oncology Announces Availability of Rubraca®▼ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. In addition, Rubraca is indicated as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-
Feb 26, 2019 08:00 am ET
Clovis Oncology Announces 2018 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2018, and provided an update on the Company’s
Feb 22, 2019 08:00 am ET
Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern time. The conference will be held at the Lotte New York Palace in New York City.
Feb 19, 2019 06:00 am ET
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
DUBLIN and BOULDER, Colo., Feb. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies have entered into a research collaboration to evaluate ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with rucaparib, Clovis' marketed PARP inhibitor, and lucitanib, Clovis' investigational tyrosine kinase inhibitor. The collaboration will explore the potential anti-cancer effects of both treatment combinations in preclinical models across multiple tumor types. Results of th
Feb 13, 2019 07:30 am ET
New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Clovis Oncology, Inc....
Feb 12, 2019 08:00 am ET
Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
Jan 24, 2019 12:28 pm ET
Clovis Oncology Announces European Commission Authorization of Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has approved the use of Rubraca® (rucaparib) for a second indication, as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. This expands rucaparib’s indication beyond its initial marketing authorization in Europe granted in May 2018 and with this label ex
Jan 07, 2019 08:00 am ET
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Jan 02, 2019 04:05 pm ET
Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:30 p.m. Pacific time. The conference will be held at the Westin St. Francis Hotel in San Francisco.
Dec 26, 2018 07:25 am ET
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), ArQule, Inc. (NASDAQ:ARQL),...
Dec 13, 2018 12:46 pm ET
CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the firs
Dec 04, 2018 07:37 am ET
Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca®
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate, including rucaparib S-camsylate Form A, the crystalline form in Rubraca.
Nov 20, 2018 08:07 am ET
Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations. The patent claims cover methods of treating cancer with commercial Rubrac
Nov 12, 2018 07:40 am ET
Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS), Evertec, Inc. (NYSE:EVTC), Etsy, Inc....
Nov 07, 2018 08:00 am ET
Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 11:30 AM Mountain Time. The conference will be held at the Phoenician in Scottsdale.
Oct 30, 2018 04:05 pm ET
Clovis Oncology Announces Third Quarter 2018 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2018, and provided an update on the Company’s
Oct 19, 2018 06:01 am ET
Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology). The data show a 44% confirmed objective res
Oct 18, 2018 09:00 am ET
Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consoli
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS), Destination Maternity Corporation...
Oct 16, 2018 08:00 am ET
Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2018 financial results on Tuesday, October 30, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Oct 11, 2018 04:05 pm ET
Clovis Oncology Appoints Two New Directors to its Board
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today the appointment of Robert W. Azelby and Richard A. Fair to the company’s Board of Directors.
Oct 03, 2018 06:00 am ET
Clovis Oncology to Highlight Results from Rubraca® (rucaparib) TRITON Prostate Program at ESMO 2018 Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four posters featuring data and highlighting studies from the Rubraca clinical development program will be presented at the ESMO 2018 Congress (European Society for Medical Oncology), 19-23 October, 2018, in Munich, Germany. These posters include the first presentation of initial results from the Phase 2 TRITON2 clinical trial of Rubraca, an oral, small molecule PARP inhibitor, in advanced mCRPC, as well as genomic profiling data based on tumor tissue and plasma cfDNA samples from patient
Oct 02, 2018 08:00 am ET
Clovis Oncology Receives Breakthrough Therapy Designation for Rubraca® (rucaparib) for Treatment of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Rubraca® (rucaparib) as a monotherapy treatment of adult patients with BRCA1/2-mutated mCRPC who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy.
Sep 06, 2018 08:00 am ET
Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 PM Eastern Time. The conference will be held at the Grand Hyatt New York in New York City.
Aug 27, 2018 07:45 am ET
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA),...
Aug 08, 2018 08:00 am ET
Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO® (nivolumab), for the treatment of advanced ovarian cancer. ATHENA, sponsored by Clovis, is part of a clinical collaboration with Bristol-Myers Squibb and is being conducted in association with the Gynecologic Oncology Group (GOG) and
Aug 01, 2018 04:05 pm ET
Clovis Oncology Announces Second Quarter 2018 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2018, and provided an update on the Company’s
Jul 18, 2018 08:00 am ET
Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Jul 05, 2018 08:00 am ET
Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca®▼ (rucaparib) as Maintenance Treatment for Women with Recurrent Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca® (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. This validation confirms the submission is complete and begins the EMA’s centralized review process.
Jun 26, 2018 07:50 am ET
Analysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology — Research Highlights Growth, Revenue, and Consolidated R
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PBF Energy Inc. (NYSE:PBF), Callaway Golf Company (NYSE:ELY), Total System...
Jun 11, 2018 04:05 pm ET
Clovis Oncology to Present at the Goldman Sachs 39th Annual Global Healthcare Conference 2018
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 4:00 PM Pacific Time. The conference will be held at the Terranea Resort in Rancho Palos Verdes, CA.
Jun 04, 2018 06:00 am ET
Clovis Oncology Submits Application to EMA to Expand Use of Rubraca®▼ (rucaparib) to Include Maintenance Treatment for Women with Recurrent Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.
Jun 03, 2018 08:00 pm ET
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
Clovis Oncology, Inc. (NASDAQ:CLVS) and Immunomedics, Inc., (NASDAQ:IMMU) today announced their intent to enter into a clinical collaboration to investigate the combination of Clovis’ Rubraca® (rucaparib), a poly (ADP ribose) polymerase inhibitor...
May 29, 2018 08:00 am ET
Clovis Oncology Announces European Commission Authorization of Rubraca® (rucaparib) for Women with Recurrent Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. Certain confirmatory post-marketing commitments are required
May 16, 2018 11:55 am ET
Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5 in Chicago.
May 09, 2018 06:08 pm ET
CORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018
Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time).
May 09, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill — Fundamental Analysis, Key Performance Indica
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalent, Inc. (NYSE:CTLT), MGIC Investment Corporation (NYSE:MTG), United...
May 08, 2018 04:05 pm ET
Clovis Oncology Announces First Quarter 2018 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2018, and provided an update on the Company’s
Apr 24, 2018 04:15 pm ET
Clovis Oncology to Announce First Quarter 2018 Financial Results and Host Webcast Conference Call on May 8
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Apr 16, 2018 08:54 pm ET
Clovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the principal amount of the notes, before underwriting discounts and commissions. Clovis also granted to the underwriters a 30-day option to purchase up to an additional $45 million aggregate principal amount of the notes on the same terms and conditions. The notes will bear interest at a rate of 1.25% per annum
Apr 16, 2018 06:44 am ET
Clovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock.
Apr 06, 2018 01:38 pm ET
Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca® (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker
Mar 23, 2018 08:52 am ET
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines.
Mar 23, 2018 08:50 am ET
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of
Mar 08, 2018 08:00 am ET
Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations. The patent is expected to issue shortly with cla
Mar 07, 2018 04:05 pm ET
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 8:00 AM Eastern Time. The conference will be held at the Loews Miami Beach Hotel in Miami.
Mar 07, 2018 08:10 am ET
Research Report Identifies Tapestry, Burlington Stores, GoDaddy, Clovis Oncology, Darden Restaurants, and General Cable with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tapestry, Inc. (NYSE:TPR), Burlington Stores, Inc....
Feb 26, 2018 04:05 pm ET
Clovis Oncology Announces 2017 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2017, and provided an update on the Company’s
Feb 26, 2018 12:30 pm ET
Clovis Oncology, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Clovis Oncology, Inc. (NASDAQ: CLVS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 4:30 PM Eastern Time.
Feb 22, 2018 08:31 am ET
Thinking about buying or selling Applied Optoelectronics Inc, Bloomin' Brands, Clovis Oncology, Roku or Wayfair?
CHICAGO, Feb. 22, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAOI, BLMN, CLVS, ROKU, and W.
Feb 21, 2018 05:10 pm ET
Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets as monotherapy for the treatment of a limited population of advanced ovarian cancer patients with deleterious BRCA mutation (germline and/or somatic). The indication under consideration by the Committee for Medicinal Products for Human Use (CHMP) focuses on a subset of platinum-sensitive disease where there is particular unmet medical need.
Feb 12, 2018 04:05 pm ET
Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Jan 04, 2018 08:00 am ET
Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco.
Dec 19, 2017 08:00 am ET
Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that the Scientific Advisory Group (SAG) on Oncology provide an opinion on aspects of the ongoing Marketing Authorization Application (MAA) relating to a potential conditional approval for rucaparib. The exact date for the SAG meeting has not yet been set but we expect it to take place in early February 2018.
Dec 05, 2017 04:05 pm ET
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
Clovis Oncology (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018. In October, Clovis completed its sNDA submission for rucaparib as maintenance treatment in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive, and in a complete or partial response to p
Nov 14, 2017 02:55 pm ET
CORRECTING and REPLACING – Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Grow
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 13th, 2017 by Fundamental Markets, please note that in the Pure Storage's Recent Financial Performance section, the first sentence has been...
Nov 13, 2017 07:50 am ET
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 13, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pure Storage, Inc. (NYSE:PSTG), Catalent, Inc....
Nov 08, 2017 06:40 pm ET
Clovis Oncology to Present at the Stifel 2017 Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 9:30 AM Eastern Time. The conference will be held at the Lotte New York Palace Hotel in New York City.
Nov 01, 2017 04:05 pm ET
Clovis Oncology Announces Third Quarter 2017 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2017, and provided an update on the Company’s
Oct 23, 2017 08:00 am ET
Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail.
Oct 09, 2017 04:05 pm ET
Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The sNDA submission is based on data from the phase 3 ARIEL3 clinical trial, which found that rucaparib significantly improved progression-free survival in all ovarian cancer
Feb 18, 2017 08:41 pm ET
Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation
SAN DIEGO, Feb. 18, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation, as detailed below:
Jan 26, 2016 09:31 am ET
Covered Call Alerts For GoPro, SolarCity, Valeant Pharmaceuticals, NetEase Inc. and Clovis Oncology Released By InvestorsObserver
CHICAGO, Jan. 26, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GPRO, SCTY, VRX, NTES and CLVS.
Dec 14, 2015 09:31 am ET
Covered Call Alerts For Gilead Sciences, Whole Foods Market, Clovis Oncology, Walmart Stores Inc. and Finisar Corporation Released By InvestorsObserver
CHICAGO, Dec. 14, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GILD, WFM, CLVS, WMT and FNSR.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.